Intracameral medication use requires careful consideration of pros and cons

Article

When thinking about administering medications intracamerally during cataract surgery, it is important to consider whether their potential benefits are worth the risk.

When thinking about administering medications intracamerally during cataract surgery, it is important to consider whether their potential benefits are worth the risk, said Nick Mamalis, MD, at Spotlight on Cataracts 2007.

Intracameral medications may be used in cataract surgery for anesthesia, pupil dilation, and to prevent inflammation and endophthalmitis. Their advantages include ease of delivery, elimination of toxicity of topical drops, avoidance of compliance issues, and possibly enhanced efficacy.

However, there are a number of downsides. Toxicity is an important risk that can occur through multiple mechanisms, which can be related to improper concentration, pH, or osmolarity. In addition, all medications used intracamerally should be preservative-free, but it is also important to be aware of toxicity related to stabilizing agents, such as are found in preservative-free epinephrine. Infectious contamination is another safety concern as is the potential for incompatibility when multiple drugs are combined.

"There are many trade-offs to consider when weighing the pros and cons of using topical drops versus intracameral medications. Intracameral medication safety can be improved if we could eliminate 'kitchen pharmacy,'" Dr. Mamalis said.

"We need sterile, pre-mixed, preservative-free, unit-dose products, and the ophthalmology community needs to work with the FDA and industry to achieve that goal," he added.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.